Pharmacology/Pharmaceutical Industry
Implementation Guide: Optimizing Medication Management during the COVID-19 Pandemic
13 Apr, 2020 | 00:18h | UTC
Related Commentary on Twitter
Task force recommendations about managing meds in post-acute and long-term care during COVID-19. https://t.co/yoU76suVYo
Summary of recommendations in thread below:
— Mike Steinman (@MikeSteinman) April 10, 2020
Review: Should Chloroquine and Hydroxychloroquine be Used to Treat COVID-19?
10 Apr, 2020 | 02:50h | UTCShould chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review – BJGP Open
“At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19”
Editorial: Chloroquine and Hydroxychloroquine in Covid-19
9 Apr, 2020 | 03:47h | UTCChloroquine and hydroxychloroquine in covid-19 – Tue BMJ
“Use of these drugs is premature and potentially harmful.”
Safety Considerations with Chloroquine, Hydroxychloroquine and Azithromycin in the Management of SARS-CoV-2 Infection
9 Apr, 2020 | 03:42h | UTC
COVID-19: More Opinions on Hydroxychloroquine
7 Apr, 2020 | 04:17h | UTCHydroxychloroquine Update For April 6 – Science Translational Medicine
The Debacle of Hydroxychloroquine and Azithromycin for COVID19 – Dr. John M.
Summary: wait for proper studies before prescribing.
Study: No Benefit from Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
6 Apr, 2020 | 01:46h | UTC
In Vitro Study: Ivermectin Inhibits Replication of SARS-CoV-2
6 Apr, 2020 | 01:49h | UTCCommentary: Possible coronavirus drug identified by Australian scientists – Monash University
Opioids in Older Adults: Indications, Prescribing, Complications, and Alternative Therapies for Primary Care
3 Apr, 2020 | 03:52h | UTC
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
2 Apr, 2020 | 04:21h | UTC
New WHO Guide to Help Countries Expand Access to Essential Medicines
2 Apr, 2020 | 03:59h | UTCSelection of essential medicines at country level – World Health Organization
News Release: New WHO Guide to help countries expand access to essential medicines – World Health Organization
‘Panic Prescribing’ Untested Coronavirus Treatments
1 Apr, 2020 | 05:51h | UTC- ‘Panic Prescribing’ Untested Coronavirus Treatments: A Danger To Patients Today and Tomorrow – Health Affairs
- We shouldn’t rush to use an unproven malaria drug to treat the coronavirus – STAT
- See also: Twitter Thread on the Latest Study Testing Hydroxychloroquine, by Lucas Morin
[Abstract Only] A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
1 Apr, 2020 | 05:39h | UTCA Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity – New England Journal of Medicine (link to abstract – $ for full-text)
COVID-19: Risks Related to the Use of Hydroxychloroquine
31 Mar, 2020 | 04:48h | UTC- Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 – American College of Cardiology
- A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 – Annals of Internal Medicine
[Preprint] COVID-19: Hydroxychloroquine Beneficial in Small Trial
31 Mar, 2020 | 04:51h | UTC
COVID-19 and Renin-Angiotensin System Blockers
30 Mar, 2020 | 02:00h | UTCRenin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers – Hypertension AND Commentary: COVID-19 alert: Heart and kidney patients should keep taking their medicines – University of Miami Miller School of Medicine
Related Guidelines: HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology AND The Renal Association, UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use AND Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers – European Society of Cardiology
#ACC20 – [Abstract only] Randomized Trial: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
30 Mar, 2020 | 01:20h | UTCRivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: PRONOMOS: Rivaroxaban Better Than Enoxaparin in Preventing VTE After Nonmajor Orthopedic Surgery – American College of Cardiology (free) AND PROphylaxis in NON-Major Orthopedic Surgery – PRONOMOS – American College of Cardiology (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
30 Mar, 2020 | 01:13h | UTCAnticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients With a Long-Term Indication for Oral Anticoagulation – POPular TAVI – American College of Cardiology (free)AND A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
30 Mar, 2020 | 01:18h | UTCVericiguat in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA – TCTMD (free) AND VICTORIA: Vericiguat Associated With Reduced CV Death, HF Hospitalization in High-Risk HF Patients – American College of Cardiology
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Rivaroxaban in Peripheral Artery Disease after Revascularization
30 Mar, 2020 | 01:05h | UTCRivaroxaban in Peripheral Artery Disease after Revascularization – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: VOYAGER-PAD: Rivaroxaban Associated With Reduced Adverse Limb, CV Events in PAD Patients – American College of Cardiology (free) AND VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – Randomized Trial: Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
30 Mar, 2020 | 01:03h | UTCSee also: Visual Abstract
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
30 Mar, 2020 | 01:12h | UTCApixaban for the Treatment of Venous Thromboembolism Associated with Cancer – New England Journal of Medicine (abstract Only – $ for full-text)
Commentaries: Caravaggio Trial: Apixaban Noninferior to Dalteparin in Treatment of Cancer-Associated VTE – American College of Cardiology (free) AND Apixaban, Dalteprin Shown to Have Same Bleeding Risk in Patients With Cancer – AJMC (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
BCCDC Position Statement on Unproven Therapies for COVID-19
27 Mar, 2020 | 03:48h | UTCRecommendation: Unproven Therapies for COVID-19 | March 24, 2020 – BC Centre for Disease Control
Randomized Trial: Aspirin Not Beneficial for Reducing the Risk of Dementia, MCI, or Cognitive Decline
26 Mar, 2020 | 02:20h | UTCCommentary: Study: An aspirin a day does not keep dementia at bay – American Academy of Neurology (free)
Hydroxychloroquine: Small Study Shows No Benefit
26 Mar, 2020 | 01:39h | UTCCommentary: Chloroquine Use For COVID-19 Shows No Benefit In First Small—But Limited—Controlled Trial – Forbes
Related: Coronavirus treatment hype can lead to harm – Lown Institute AND No, These Medicines Cannot Cure Coronavirus – The New York times
See also: Chloroquine for COVID-19: Cutting Through the Hype
Pill Splitting: Making the Most of Meds in a Time of Need
25 Mar, 2020 | 02:29h | UTC